Urinary metabolomic fingerprinting after consumption of a probiotic strain in women with mastitis.

Rosa Vázquez-Fresno, Rafael Llorach, Jelena Marinic, Sara Tulipani, Mar Garcia-Aloy, Irene Espinosa-Martos, Esther Jiménez, Juan Miguel Rodríguez, Cristina Andres-Lacueva

Journal: Pharmacological research 2015;87():160-5

PMID: 24880136

Abstract

Infectious mastitis is a common condition among lactating women, with staphylococci and streptococci being the main aetiological agents. In this context, some lactobacilli strains isolated from breast milk appear to be particularly effective for treating mastitis and, therefore, constitute an attractive alternative to antibiotherapy. A (1)H NMR-based metabolomic approach was applied to detect metabolomic differences after consuming a probiotic strain (Lactobacillus salivarius PS2) in women with mastitis. 24h urine of women with lactational mastitis was collected at baseline and after 21 days of probiotic (PB) administration. Multivariate analysis (OSC-PLS-DA and hierarchical clustering) showed metabolome differences after PB treatment. The discriminant metabolites detected at baseline were lactose, and ibuprofen and acetaminophen (two pharmacological drugs commonly used for mastitis pain), while, after PB intake, creatine and the gut microbial co-metabolites hippurate and TMAO were detected. In addition, a voluntary desertion of the pharmacological drugs ibuprofen and acetaminophen was observed after probiotic administration. The application of NMR-based metabolomics enabled the identification of the overall effects of probiotic consumption among women suffering from mastitis and highlighted the potential of this approach in evaluating the outcomes of probiotics consumption. To our knowledge, this is the first time that this approach has been applied in women with mastitis during lactation.

Copyright © 2014. Published by Elsevier Ltd.

Address: Biomarkers and Nutrimetabolomic Lab., Nutrition and Food Science Department, XaRTA, INSA, Torribera Campus, Pharmacy Faculty, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; INGENIO-CONSOLIDER Programme, Fun-c-food CSD2007-063, Ministry of Science and Innovation, Barcelona, Spain.; Biomarkers and Nutrimetabolomic Lab., Nutrition and Food Science Department, XaRTA, INSA, Torribera Campus, Pharmacy Faculty, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; INGENIO-CONSOLIDER Programme, Fun-c-food CSD2007-063, Ministry of Science and Innovation, Barcelona, Spain. Electronic address: [email protected].; Department of Chemistry and Biochemistry, School of Medicine, University of Rijeka, Brace Brancetta 20, 51 000 Rijeka, Croatia.; Biomarkers and Nutrimetabolomic Lab., Nutrition and Food Science Department, XaRTA, INSA, Torribera Campus, Pharmacy Faculty, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain; INGENIO-CONSOLIDER Programme, Fun-c-food CSD2007-063, Ministry of Science and Innovation, Barcelona, Spain; Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, Málaga Hospital Complex (Virgen de la Victoria), Campus de Teatinos s/n, University of Málaga, Málaga 29010, Spain.; INGENIO-CONSOLIDER Programme, Fun-c-food CSD2007-063, Ministry of Science and Innovation, Barcelona, Spain; Department of Nutrition, Food Science and Technology, Complutense University of Madrid, Avda. Puerta de Hierro, s/n, 28040 Madrid, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.